Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 8;40:315. doi: 10.1186/s13046-021-02120-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — WEE1 inhibitor MK1775 enhances the anticancer effect of immune checkpoint blockade (ICB) therapy in MUS81 deficient gastric cancer cells. a Schematic of isotype control IgG, MK1775, anti–PD-L1 antibody and combination treatment. Treatments were started on day 7 after inoculation and stopped on day 29. b Tumor volume of the indicated groups on day 29. Data of tumor volume are represented as mean ± SD (n = 6 for each group). c Tumor growth curve of indicated groups. Data of tumor volume are represented as mean ± SD in indicated groups (n = 6 for each group). d Images of tumor of MFC gastric cancer mice model. e multiplexed immunofluorescence (mIF) staining of CD8 (red), perforin (green), and PD-L1 (pink) in parental and MUS81 knockdown MFC tumors. Scale bar: 50 μm. f Quantitative analysis of CD8 and PD-L1 positive cells and the fluorescence intensity of perforin. Top, proportion of CD8 positive cells in MFC shScramble (left) or shMUS81 (right) tumors. Middle, proportion of PD-L1 positive cells in MFC shScramble (left) or shMUS81 (right) tumors; Bottom, the fluorescence intensity of perforin in MFC shScramble (left) or shMUS81 (right) tumors. The data are presented as mean ± SD (n = 3). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns., not significant